Orforglipron: The First Oral Non-Peptide GLP-1 Pill
The first oral, non-peptide GLP-1 receptor agonist pill with no food or water restrictions — FDA-approved in 2026 as Foundayo.
What is Orforglipron?
Orforglipron is a fundamentally different kind of GLP-1 medicine: a small-molecule, non-peptide oral GLP-1 receptor agonist, taken as a once-daily tablet at any time of day, with or without food — unlike semaglutide's oral form (Rybelsus), which must be taken fasted with a small sip of water and a 30-minute food/drink delay. Developed by Eli Lilly under the development code LY3502970, orforglipron received FDA approval on April 1, 2026 under the brand name Foundayo, for adults with obesity or overweight with a weight-related medical problem. Its inclusion here alongside injectable peptides mirrors how MK-677 — also a non-peptide, orally active compound — sits in REGEN's catalog as a notable exception to the peptide-only norm.
Quick facts
- Development Code
- LY3502970
- Half-Life
- ~29–49 hours
- Class
- Non-peptide, oral small-molecule GLP-1 receptor agonist
- Solubility
- Oral tablet — no reconstitution required
- Brand Names
- Foundayo
- Legal Status
- Prescription-only, FDA-approved (April 2026)
- Category
- Metabolic / Weight Loss
- Storage
- Room temperature, sealed, away from light and moisture. No refrigeration or reconstitution required.
Dosing at a glance
Doses shown are those reported in published research, not a recommendation.
Orforglipron Mechanism of Action
A Non-Peptide GLP-1
Orforglipron is not a peptide — it's a small-molecule, non-peptide compound that activates the GLP-1 receptor, engineered to survive digestion intact and absorb through the gut without the specialized absorption-enhancer technology semaglutide's oral form (Rybelsus) requires. Structurally unrelated to native GLP-1 or exendin-4, it was designed from the ground up as an orally bioavailable small molecule rather than a modified peptide.
No Food or Water Restrictions
The defining practical advantage of orforglipron over Rybelsus (oral semaglutide) is dosing flexibility: it can be taken any time of day, with or without food, with no fasting requirement and no minimum water intake rule. This removes the biggest adherence barrier of the prior oral GLP-1 option, where a missed fasting window meant a missed effective dose.
Orforglipron Dosage and Protocols
Tablet Titration
Orforglipron is available in six tablet strengths — 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg, and 17.2mg — taken once daily, with the dose titrated upward gradually to limit gastrointestinal side effects, following the same general titrate-slowly principle used across the GLP-1 class.
Orforglipron Side Effects and Safety
Common and Serious Risks
As with other GLP-1 receptor agonists, the most common side effects are gastrointestinal — nausea, diarrhea, constipation, and vomiting — typically most pronounced during dose titration. The class boxed warning for medullary thyroid carcinoma risk (based on rodent data) applies. Pancreatitis, gallbladder disease, and pregnancy are contraindications shared across the GLP-1 class.
Orforglipron Research Evidence
FDA Approval
Orforglipron, developed by Eli Lilly under development code LY3502970, received FDA approval on April 1, 2026 under the brand name Foundayo, for adults with obesity, or overweight with at least one weight-related medical problem. It is the first oral GLP-1 pill approved with no food or water restrictions.
Regulatory and Legal Status
Orforglipron is prescription-only and FDA-approved as of April 2026. It is a legitimate, approved pharmaceutical and should only be obtained through a licensed prescriber and pharmacy — not through unregulated research-chemical channels, regardless of how it may be marketed there.
Orforglipron Stacking and Combinations
Standalone Oral Therapy
As a newly approved oral medication, orforglipron is prescribed as a standalone weight-management therapy through standard medical channels, not as part of an informal peptide-stacking protocol.
Orforglipron Pharmacokinetics
Oral Absorption
Orforglipron is absorbed through the gastrointestinal tract without requiring the specialized absorption-enhancer (SNAC) technology that oral semaglutide depends on, which is what allows it to be dosed without fasting. Its half-life of roughly 29–49 hours supports once-daily oral dosing with steady accumulation over the first 1–2 weeks of a given dose level.
Contraindications
- personal/family history of medullary thyroid carcinoma
- MEN 2
- pancreatitis
- pregnancy
Frequently asked questions
What is a typical Orforglipron dose?
Published research protocols report 0.8–17.2 mg, 1x daily (titrated). This is the range described in the literature, not a recommendation.
What is the half-life of Orforglipron?
~29–49 hours (once-daily oral dosing).
Is Orforglipron backed by strong evidence?
Orforglipron carries a REGEN research grade of S. REGEN Research Tier S — official FDA approval as Foundayo, April 2026.
How is Orforglipron administered?
Routes reported in the literature: oral.
Who should avoid Orforglipron?
Contraindications noted in the literature include personal/family history of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy.